| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Inarigivir (formerly also known as ORI-9020; SB-9000) is a novel and potent dinucleotide which can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. It was evaluated in transgenic mice expressing hepatitis B virus (HBV), significantly reduced liver HBV DNA (P
| ln Vitro |
The nucleos(t)ide analogs authorized for the treatment of chronic hepatitis B are all susceptible to resistance markers when it comes to HBV variations that are active against inarigivir (SB 9200) [2].
|
|---|---|
| ln Vivo |
Inarigivir (100 mg/kg/day, i.p.) shown anti-HBV efficacy and markedly decreased the amount of viral DNA in the liver. Treatment has no effect on the level of serum HBV DNA. Serum HBeAg levels, mean HBsAg titers, and liver HBV RNA levels were all unaffected by inarigivir. Based on liver HBV DNA levels, the lowest effective dose is 1.6 to 0.5 mg/kg/day [1].
|
| Animal Protocol |
Animal/Disease Models: Mice[1]
Doses: 100 mg/kg. Management: IP, daily. Experimental Results: Viral DNA was Dramatically diminished in the liver and demonstrated anti-HBV activity similar to the ADV positive control. |
| References |
[1]. Iyer RP, et al. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob Agents Chemother. 2004 Jun;48(6):2318-20.
[2]. Danni Colledge, et al. The Novel Antiviral Agent Inarigivir Inhibits Both Nucleos(t)ide Analogue and Capsid Assembly Inhibitor Resistant HBV in vitro. |
| Molecular Formula |
C20H26N7O10PS
|
|---|---|
| Molecular Weight |
587.500103473663
|
| CAS # |
475650-36-3
|
| Related CAS # |
Inarigivir ammonium;2172788-92-8
|
| SMILES |
O=P(OC[C@H]1O[C@@H](N2C=NC3=C(N)N=CN=C23)C[C@@H]1O)(S)O[C@@H]4[C@@H](CO)O[C@@H](N(C(N5)=O)C=CC5=O)[C@@H]4OC
|
| InChi Key |
LYMICVBGNUEHGE-FUQPUAIBSA-N
|
| InChi Code |
InChI=1S/C20H26N7O10PS/c1-33-16-15(10(5-28)36-19(16)26-3-2-12(30)25-20(26)31)37-38(32,39)34-6-11-9(29)4-13(35-11)27-8-24-14-17(21)22-7-23-18(14)27/h2-3,7-11,13,15-16,19,28-29H,4-6H2,1H3,(H,32,39)(H2,21,22,23)(H,25,30,31)/t9-,10+,11+,13+,15+,16+,19+,38?/m0/s1
|
| Chemical Name |
O-(((2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl) O-((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-yl) S-hydrogen phosphorothioate
|
| Synonyms |
Inarigivir soproxil; ORI-9020; ORI 9020; ORI9020; SB-40; SB-9000; SB9000, SB-9000.
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~200 mg/mL (~340.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.26 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.26 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.25 mg/mL (0.43 mM) (saturation unknown) in 1% DMSO 99% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7021 mL | 8.5106 mL | 17.0213 mL | |
| 5 mM | 0.3404 mL | 1.7021 mL | 3.4043 mL | |
| 10 mM | 0.1702 mL | 0.8511 mL | 1.7021 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 Southern blot hybridization for HBV DNA in the livers of mice treated i.p. with ORI-9020, ADV, or vehicle only.Antimicrob Agents Chemother. 2004 Jun; 48(6): 2318–2320. |
|---|
 Determination of minimal effective concentration of ORI-9020 using liver HBV DNA parameter in transgenic mice.Antimicrob Agents Chemother. 2004 Jun; 48(6): 2318–2320. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA